Aeromics, LLC
New Haven, US · Founded 2016 · Delaware corporation · 2 known investors
Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenous aquaporin-4 (AQP4) inhibitor designed to prevent cerebral edema (brain swelling) following severe, acute ischemic stroke. Its approach targets molecular water channels to improve outcomes in neurological indications such as stroke, spinal cord injury, CNS surgery, and brain cancer.
Founders & leadership
Aeromics, LLC was founded in 2016 by Dr. Pelletier, Dr. Boron, and William Boron.
DP
Dr. PelletierCo-founder
DB
Dr. BoronFounder
WB
William BoronCo-founder
PM
Paul McGuirkExecutive
GF
George FarrExecutive
TZ
Thomas ZindrickExecutive Chairman
TT
Trevor ThompsonPresident
DJ
Dave JenkinsVP Finance
WB
Walter BoronNamed on SEC filing
MP
Marc PelletierManager, Chief Executive Officer
Board
FJ
Frederick JonesBoard director
PL
Investors · 2
Reported raises · per SEC filings
Form D private placements$14.1M disclosed across 4 rounds · 2014–2017
▶$9.4MraisedDec 2018 · 57 investors · BiotechnologyRule 506(b)
▶$9.4MraisedDec 2018 · 57 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter LongoDirector
- Jeffrey DraimeDirector
- Mark DayDirector
- Thomas ZindrickDirector
- Christine AntalikExecutive Officer
- Marc F. PelletierExecutive Officer, Director
- Offering amount
- $11.1M
- Amount sold
- $9.4M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$1.5MraisedJul 2017 · 11 investors · BiotechnologyRule 506(b)
▶$1.5MraisedJul 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Walter BoronExecutive Officer, Director
- Frederick JonesDirector
- Peter LongoDirector
- Paul SchlatherDirector
- Paul McGuirkExecutive Officer
- George FarrExecutive Officer
- Jeff DraimeDirector
- John FosterDirector
- Marc F. PelletierExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.5M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedApr 2016 · 5 investors · BiotechnologyRule 506(b)
▶$1.9MraisedApr 2016 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frederick JonesDirector
- Paul McGuirkExecutive Officer
- Peter LongoDirector
- Walter BoronExecutive Officer, Director
- George FarrExecutive Officer
- Marc F. PelletierExecutive Officer, Director
- John FosterDirector
- Offering amount
- $3M
- Amount sold
- $1.9M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMar 2014 · 15 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMar 2014 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Walter BoronExecutive Officer, Director
- Marc PelletierExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.3M
- Minimum investment
- $15K
- First sale
- Feb 2014
- Incorporated
- Limited Liability Company, Connecticut
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Aeromics, LLC do?
- Aeromics is a clinical-stage pharmaceutical company developing AER-271, an intravenous aquaporin-4 (AQP4) inhibitor designed to prevent cerebral edema (brain swelling) following severe, acute ischemic stroke. Its approach targets molecular water channels to improve outcomes in neurological indications such as stroke, spinal cord injury, CNS surgery, and brain cancer.
- Who founded Aeromics, LLC?
- Aeromics, LLC was founded by Dr. Pelletier, Dr. Boron, William Boron in 2016.
- Who are Aeromics, LLC's investors?
- Aeromics, LLC's investors include Broadview Ventures, Connecticut Innovations.
- How much funding has Aeromics, LLC raised?
- Aeromics, LLC has disclosed $14.1M raised across 4 rounds.
- Where is Aeromics, LLC headquartered?
- Aeromics, LLC is headquartered in New Haven, US.